Cowen Royalty Buyers In “Right Place, Right Time”
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal to purchase royalty stream from LifeCycle exemplifies what deal-makers want in tight equity market.
You may also be interested in...
Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.
Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.